These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1135 related articles for article (PubMed ID: 24882836)

  • 1. A population-based study showing better renal prognosis for proteinase 3 antineutrophil cytoplasmic antibody (ANCA)-associated nephritis versus myeloperoxidase ANCA-associated nephritis.
    Mohammad AJ; Segelmark M
    J Rheumatol; 2014 Jul; 41(7):1366-73. PubMed ID: 24882836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics of patients with vasculitis positive for anti-neutrophil cytoplasmic antibody targeting both proteinase 3 and myeloperoxidase: a retrospective study.
    Kim SM; Choi SY; Kim SY; Kim J
    Rheumatol Int; 2019 Nov; 39(11):1919-1926. PubMed ID: 31552433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myeloperoxidase-antineutrophil Cytoplasmic Antibodies (MPO-ANCA) and Proteinase 3-ANCA without Immunofluorescent ANCA Found by Routine Clinical Testing.
    Rao DA; Wei K; Merola JF; O'Brien WR; Takvorian SU; Dellaripa PF; Schur PH
    J Rheumatol; 2015 May; 42(5):847-52. PubMed ID: 25834211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Berti A; Warner R; Johnson K; Cornec D; Schroeder D; Kabat B; Langford CA; Hoffman GS; Fervenza FC; Kallenberg CGM; Seo P; Spiera R; St Clair EW; Brunetta P; Stone JH; Merkel PA; Specks U; Monach PA;
    Arthritis Rheumatol; 2018 Jul; 70(7):1114-1121. PubMed ID: 29693324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinction between MPO-ANCA and PR3-ANCA-associated glomerulonephritis in Chinese patients: a retrospective single-center study.
    Hong Y; Shi P; Liu X; Yang L; Li K; Xu F; Liang S; Liu Z; Zhang H; Chen Y; Hu W
    Clin Rheumatol; 2019 Jun; 38(6):1665-1673. PubMed ID: 30737591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type.
    Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U;
    Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Difference in relapse-rate and clinical phenotype by autoantibody-subtype in Japanese patients with anti-neutrophil cytoplasmic antibody-associated vasculitis.
    Murosaki T; Sato T; Akiyama Y; Nagatani K; Minota S
    Mod Rheumatol; 2017 Jan; 27(1):95-101. PubMed ID: 27320904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and prognostic features of Korean patients with MPO-ANCA, PR3-ANCA and ANCA-negative vasculitis.
    Yoo J; Kim HJ; Ahn SS; Jung SM; Song JJ; Park YB; Lee SW
    Clin Exp Rheumatol; 2017; 35 Suppl 103(1):111-118. PubMed ID: 28339364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Histological Subtyping of Immune Cell Infiltrates in MPO-ANCA and PR3-ANCA Glomerulonephritis.
    Hakroush S; Tampe D; Ströbel P; Korsten P; Tampe B
    Front Immunol; 2021; 12():737708. PubMed ID: 34759920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and histopathological prognostic factors affecting the renal outcomes in childhood ANCA-associated vasculitis.
    Özçelik G; Sönmez HE; Şahin S; Özağarı A; Bayram MT; Çiçek RY; Çakıcı EK; Çomak E; Barut K; Şahin N; Bakkaloğlu S; Gökçe İ; Düzova A; Bilginer Y; Açarı C; Melek E; Kılıç BD; Özdel S; Adroviç A; Kasapçopur Ö; Ünsal E; Alpay H; Orhan D; Topaloğlu R; Düşünsel R; Özen S
    Pediatr Nephrol; 2019 May; 34(5):847-854. PubMed ID: 30607566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients.
    Geffriaud-Ricouard C; Noël LH; Chauveau D; Houhou S; Grünfeld JP; Lesavre P
    Clin Nephrol; 1993 Mar; 39(3):125-36. PubMed ID: 7681736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged infections associated with antineutrophil cytoplasmic antibodies specific to proteinase 3 and myeloperoxidase: diagnostic and therapeutic challenge.
    Bonaci-Nikolic B; Andrejevic S; Pavlovic M; Dimcic Z; Ivanovic B; Nikolic M
    Clin Rheumatol; 2010 Aug; 29(8):893-904. PubMed ID: 20306213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity.
    Vizjak A; Rott T; Koselj-Kajtna M; Rozman B; Kaplan-Pavlovcic S; Ferluga D
    Am J Kidney Dis; 2003 Mar; 41(3):539-49. PubMed ID: 12612976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ANCA positive crescentic glomerulonephritis outcome in a Central East European cohort: a retrospective study.
    Andreiana I; Stancu S; Avram A; Taran L; Mircescu G
    BMC Nephrol; 2015 Jun; 16():90. PubMed ID: 26123651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteinase 3-ANCA Vasculitis versus Myeloperoxidase-ANCA Vasculitis.
    Hilhorst M; van Paassen P; Tervaert JW;
    J Am Soc Nephrol; 2015 Oct; 26(10):2314-27. PubMed ID: 25956510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis.
    Lionaki S; Blyth ER; Hogan SL; Hu Y; Senior BA; Jennette CE; Nachman PH; Jennette JC; Falk RJ
    Arthritis Rheum; 2012 Oct; 64(10):3452-62. PubMed ID: 23023777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and immunological features of drug-induced and infection-induced proteinase 3-antineutrophil cytoplasmic antibodies and myeloperoxidase-antineutrophil cytoplasmic antibodies and vasculitis.
    Csernok E; Lamprecht P; Gross WL
    Curr Opin Rheumatol; 2010 Jan; 22(1):43-8. PubMed ID: 19770659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical features and prognosis of ANCA-associated vasculitis patients who were double-seropositive for myeloperoxidase-ANCA and proteinase 3-ANCA.
    Gong Y; Shen C; Meng T; Lin W; Hu X; Tang R; Xiong Q; Ooi JD; Eggenhuizen PJ; Chen J; Zhou YO; Luo H; Xu J; Liu N; Xiao P; Xiao X; Zhong Y
    Clin Exp Med; 2024 Apr; 24(1):66. PubMed ID: 38564029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody subtypes and titers predict clinical outcomes in ANCA-associated vasculitis.
    Aljuhani M; Makati D; Hoff A; Thompson J; Pellegrino B; Shawwa K; Schmidt R; Kannabhiran D
    Rheumatol Int; 2021 May; 41(5):965-972. PubMed ID: 33585954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between serologic profile (ANCA type) and clinical features of renal involvement in ANCA-associated vasculitides.
    Bulanov NM; Makarov EA; Shchegoleva EM; Zykova AS; Vinogradova ES; Novikov PI; Lysenko Kozlovskaya LV; Moiseev SV
    Ter Arkh; 2018 Jun; 90(6):15-21. PubMed ID: 30701899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.